ruxolitinib
Incyte’s ruxolitinib cream formulations look strong in Phase 3 atopic dermatitis
April 7, 2020Manufacturing and Production, Research and Development Incyte, atopic dermatitis, ruxolitinib
Incyte has lifted the curtain on promising new Phase 3 data for its 0.75% and 1.5% twice daily cream formulations …
Novartis blood cancer drug given EU nod
March 17, 2015Sales and Marketing Cancer, EU, Jakavi, Novartis, oncology, polycythemia vera, ruxolitinib
Novartis’ blood cancer drug Jakavi has been given the green light in Europe to treat adult patients with polycythemia vera …
Novartis earns EMA and FDA nods for Jakavi and Bexsero
January 26, 2015Sales and Marketing Bexsero, Cancer, EU, FDA, Jakavi, Novartis, US, meningitis, ruxolitinib
Novartis has secured the regulatory go-ahead for two of its drugs, after the EMA recommended Jakavi for a rare blood …
Novartis plans Q2 filing for blood cancer drug
March 17, 2011Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib
Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …
Latest content
Five Facts about cardiovascular disease
August 9, 2026
